CompoAtlas

Optisom

Optisom, licence 80046576: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Licence holder
ATP ATHLÉTIQUE ET THÉRAPEUTIQUE PHARMA INC. ou ATP ATHLETIC AND THERAPEUTIC PHARMA INC.
NPN or DIN-HM
80046576
Status
Inactive licence
Licence date
27 November 2013
Revision date
21 March 2017
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Matricaria chamomilla

Source : Fleur

Extraction ratio : 100:1

Dry plant equivalent : 2000 mg

20.0 mgNot calculated
Acide gamma-aminobutyrique

Source : Acide 4-aminobutanoïque

125.0 mgNot calculated
Scutellaria lateriflora

Source : Feuille

Extraction ratio : 100:1

Dry plant equivalent : 2000 mg

20.0 mgNot calculated
Passiflora incarnata

Source : Feuille

Extraction ratio : 100:1

Dry plant equivalent : 2000 mg

20.0 mgNot calculated
Valeriana officinalis

Source : Racine

Extraction ratio : 100:1

Dry plant equivalent : 1500 mg

15.0 mgNot calculated
Vitamine B6

Source : 5-phosphate de pyridoxal

2.5 mg2,500 µg

Non-medicinal ingredients

Cire de Carnauba, Gélatine, L-Leucine, Hydroxymethyl cellulose, Alginate de sodium, Farine de riz brun, Stéarate de magnésium, Cellulose microcristalline

PopulationAgeQuantity per servingFrequency
AdultesNot specified1.0 Capsule1.0 Jour(s)

Uses authorised in Canada

Helps to temporarily promote relaxation. Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule. Helps to reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people with delayed sleep phase disorder. Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80046576

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2017. Photograph the packaging to check whether it has changed.

Has the product changed? Photograph the packaging.

List recorded in 2017. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line